PL2265261T3 - Systemy dostarczania leku zawierające słabo zasadowe leki i kwasy organiczne - Google Patents

Systemy dostarczania leku zawierające słabo zasadowe leki i kwasy organiczne

Info

Publication number
PL2265261T3
PL2265261T3 PL09718989T PL09718989T PL2265261T3 PL 2265261 T3 PL2265261 T3 PL 2265261T3 PL 09718989 T PL09718989 T PL 09718989T PL 09718989 T PL09718989 T PL 09718989T PL 2265261 T3 PL2265261 T3 PL 2265261T3
Authority
PL
Poland
Prior art keywords
drug delivery
organic acids
delivery systems
weakly basic
basic drugs
Prior art date
Application number
PL09718989T
Other languages
English (en)
Inventor
Gopi Venkatesh
Jin-Wang Lai
Nehal H. Vyas
Vivek Purohit
Original Assignee
Adare Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41063296&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2265261(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Adare Pharmaceuticals Inc filed Critical Adare Pharmaceuticals Inc
Publication of PL2265261T3 publication Critical patent/PL2265261T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
PL09718989T 2008-03-12 2009-03-11 Systemy dostarczania leku zawierające słabo zasadowe leki i kwasy organiczne PL2265261T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3584008P 2008-03-12 2008-03-12
US12/209,285 US8133506B2 (en) 2008-03-12 2008-09-12 Drug delivery systems comprising weakly basic drugs and organic acids

Publications (1)

Publication Number Publication Date
PL2265261T3 true PL2265261T3 (pl) 2017-01-31

Family

ID=41063296

Family Applications (1)

Application Number Title Priority Date Filing Date
PL09718989T PL2265261T3 (pl) 2008-03-12 2009-03-11 Systemy dostarczania leku zawierające słabo zasadowe leki i kwasy organiczne

Country Status (24)

Country Link
US (1) US8133506B2 (pl)
EP (1) EP2265261B1 (pl)
JP (1) JP5634882B2 (pl)
KR (1) KR101660927B1 (pl)
CN (1) CN101977593B (pl)
AR (1) AR071562A1 (pl)
AU (1) AU2009223019C1 (pl)
BR (1) BRPI0908942A2 (pl)
CA (1) CA2718257C (pl)
CL (1) CL2009000598A1 (pl)
DK (1) DK2265261T3 (pl)
ES (1) ES2590479T3 (pl)
HU (1) HUE029680T2 (pl)
IL (1) IL208089A0 (pl)
MX (1) MX2010010052A (pl)
NZ (1) NZ587897A (pl)
PL (1) PL2265261T3 (pl)
PT (1) PT2265261T (pl)
RU (1) RU2504362C2 (pl)
SA (1) SA109300166B1 (pl)
SG (1) SG10201405929UA (pl)
TW (1) TWI440480B (pl)
WO (1) WO2009114606A1 (pl)
ZA (1) ZA201006557B (pl)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1976492B8 (en) * 2006-01-27 2018-07-04 Adare Pharmaceuticals, Inc. Drug delivery systems comprising weakly basic drugs and organic acids
ES2531215T3 (es) * 2006-01-27 2015-03-11 Aptalis Pharmatech Inc Sistemas de administración de fármacos que comprenden un agente de bloqueo selectivo de la serotonina 5-HT3 débilmente básico y ácidos orgánicos
CA2725754C (en) 2008-06-11 2017-05-23 Hazel Joan Dyke Diazacarbazoles and methods of use
US20100260858A1 (en) * 2009-04-09 2010-10-14 Elan Pharma International Limited Drug delivery composition
US20110003005A1 (en) * 2009-07-06 2011-01-06 Gopi Venkatesh Methods of Treating PDNV and PONV with Extended Release Ondansetron Compositions
CN102048705B (zh) * 2009-11-10 2012-07-18 齐鲁制药有限公司 盐酸帕洛诺司琼口腔崩解片制剂及其制备方法
EP2506835B1 (en) 2009-11-30 2019-06-12 Adare Pharmaceuticals, Inc. Compressible-coated pharmaceutical compositions and tablets and methods of manufacture
WO2011082426A1 (en) * 2010-01-04 2011-07-07 Eurand, Inc. Controlled release compositions comprising meclizine or related piperazine derivatives
US20120164233A1 (en) * 2010-07-30 2012-06-28 Ranbaxy Laboratories Limited Pulsatile release pharmaceutical formulation of dexlansoprazole
CH705678B1 (de) * 2010-08-13 2016-03-15 Euro Celtique Sa Verwendung von Bindemitteln zur Herstellung von lagerungsstabilen Formulierungen.
US9011912B2 (en) 2010-10-07 2015-04-21 Abon Pharmaceuticals, Llc Extended-release oral dosage forms for poorly soluble amine drugs
CA2819663C (en) 2010-12-02 2019-12-24 Aptalis Pharmatech, Inc. Rapidly dispersing granules, orally disintegrating tablets and methods
CN107412173A (zh) 2010-12-23 2017-12-01 普渡制药公司 抗篡改固体口服剂型
DK2861236T3 (da) * 2012-06-15 2019-10-14 Pharmathen Sa Farmaceutisk sammensætning, der indeholder phosphatbindende polymer
MX2015010041A (es) 2013-02-05 2015-10-30 Purdue Pharma Lp Formulacion farmaceuticas resistentes a la alteracion.
US10751287B2 (en) 2013-03-15 2020-08-25 Purdue Pharma L.P. Tamper resistant pharmaceutical formulations
WO2015038854A1 (en) * 2013-09-13 2015-03-19 R.P. Scherer Technologies, Llc Encased-pellet tablets
CN105797162B (zh) * 2014-12-31 2022-10-25 昆明积大制药股份有限公司 药用辅料表面改性方法

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3634584A (en) 1969-02-13 1972-01-11 American Home Prod Sustained action dosage form
GB1468172A (en) 1973-03-28 1977-03-23 Benzon As Alfred Oral drug preparations
US3954959A (en) 1973-03-28 1976-05-04 A/S Alfred Benzon Oral drug preparations
DE2336218C3 (de) 1973-07-17 1985-11-14 Byk Gulden Lomberg Chemische Fabrik Gmbh, 7750 Konstanz Orale Arzneiform
DD146547A5 (de) 1978-07-15 1981-02-18 Boehringer Sohn Ingelheim Arzneimittel-retardform mit unloeslichen poroesen diffusionshuellen
IE48715B1 (en) 1978-12-22 1985-05-01 Elan Corp Plc New galencial forms for administration of medicaments by oral route,with programmed release and processes for preparing same
DE3000979A1 (de) 1980-01-12 1981-07-23 Dr. Karl Thomae Gmbh, 7950 Biberach Neue dipyridamol-retardformen und verfahren zu ihrer herstellung
DE3124090A1 (de) 1981-06-19 1983-01-05 Dr. Karl Thomae Gmbh, 7950 Biberach Neue orale dipyridamolformen
DE3126703A1 (de) 1981-07-07 1983-01-27 Dr. Karl Thomae Gmbh, 7950 Biberach Bromhexin-retardform und verfahren zu ihrer herstellung
DE3237575A1 (de) 1982-10-09 1984-04-12 Dr. Karl Thomae Gmbh, 7950 Biberach Neue orale mopidamolformen
IE55745B1 (en) 1983-04-06 1991-01-02 Elan Corp Plc Sustained absorption pharmaceutical composition
IE56459B1 (en) 1983-12-21 1991-08-14 Elan Corp Ltd Controlled absorption pharmaceutical formulation
IE56999B1 (en) 1983-12-22 1992-03-11 Elan Corp Plc Pharmaceutical formulation
US4894240A (en) 1983-12-22 1990-01-16 Elan Corporation Plc Controlled absorption diltiazem formulation for once-daily administration
EP0225085A1 (en) 1985-11-13 1987-06-10 ELAN CORPORATION, Plc Controlled absorption pharmaceutical formulation
IE58401B1 (en) 1986-06-20 1993-09-08 Elan Corp Plc Controlled absorption pharmaceutical composition
DE3627423A1 (de) 1986-08-13 1988-02-18 Thomae Gmbh Dr K Arzneimittel enthaltend dipyridamol oder mopidamol und o-acetylsalicylsaeure bzw. deren physiologisch vertraegliche salze, verfahren zu ihrer herstellung und ihre verwendung zur bekaempfung der thrombusbildung
DK0585355T3 (da) 1991-05-20 1995-06-06 Tanabe Seiyaku Co Flerlagspræparat med reguleret frigivelse
US5705190A (en) 1995-12-19 1998-01-06 Abbott Laboratories Controlled release formulation for poorly soluble basic drugs
US5840329A (en) 1997-05-15 1998-11-24 Bioadvances Llc Pulsatile drug delivery system
EP1058538B9 (en) 1998-03-06 2013-01-02 Aptalis Pharma S.r.l. Fast disintegrating tablets
US6602521B1 (en) 1998-09-29 2003-08-05 Impax Pharmaceuticals, Inc. Multiplex drug delivery system suitable for oral administration
DK1126826T6 (en) * 1998-11-02 2019-06-24 Alkermes Pharma Ireland Ltd Multiparticulate modified release of methylphenidate
US6936275B2 (en) 1999-12-20 2005-08-30 Scolr, Inc. Amino acid modulated extended release dosage form
AU3289301A (en) 2000-01-20 2001-07-31 Delsys Pharmaceutical Corporation Multi-step drug dosage forms
US6627223B2 (en) * 2000-02-11 2003-09-30 Eurand Pharmaceuticals Ltd. Timed pulsatile drug delivery systems
US6500457B1 (en) * 2000-08-14 2002-12-31 Peirce Management, Llc Oral pharmaceutical dosage forms for pulsatile delivery of an antiarrhythmic agent
SK6182003A3 (en) 2000-10-30 2004-03-02 Teva Pharma Crystalline and solvated forms of ondansetrone hydrochloride and preparation thereof
DE10149674A1 (de) 2001-10-09 2003-04-24 Apogepha Arzneimittel Gmbh Orale Darreichungsformen für Propiverin oder seinen pharmazeutisch annehmbaren Salzen mit verlängerter Wirkstoffreisetzung
US20040019096A1 (en) 2001-10-23 2004-01-29 Vlassios Andronis Novel formulations of carvedilol
US6663888B2 (en) 2001-12-14 2003-12-16 Eurand Pharmaceuticals Ltd. Pulsatile release histamine H2 antagonist dosage form
US8323693B2 (en) * 2002-03-14 2012-12-04 Medrx Co., Ltd. External preparation for wounds
US7939102B2 (en) 2002-06-07 2011-05-10 Torrent Pharmaceuticals Ltd. Controlled release formulation of lamotrigine
WO2004096182A1 (en) 2003-04-30 2004-11-11 Ranbaxy Laboratories Limited Extended release matrix tablets of carvedilol
GB0317663D0 (en) * 2003-07-29 2003-09-03 Astrazeneca Ab Pharmaceutical composition
RS20050835A (en) 2004-01-06 2007-08-03 Panacea Biotec Ltd., Compositions of buccal dosage forms for extended drug release and the process of preparing such compositions
WO2005077341A1 (en) 2004-01-19 2005-08-25 Ranbaxy Laboratories Limited Orally disintegrating pharmaceutical compositions of ondansetron
US8545881B2 (en) 2004-04-19 2013-10-01 Eurand Pharmaceuticals, Ltd. Orally disintegrating tablets and methods of manufacture
JP4277904B2 (ja) * 2004-04-30 2009-06-10 アステラス製薬株式会社 経口投与用時限放出型粒子状医薬組成物及び該組成物を含有する口腔内速崩壊錠
CN101132777A (zh) * 2004-12-20 2008-02-27 科利吉姆制药公司 用于睡眠障碍的药物组合物
US20060280795A1 (en) 2005-06-08 2006-12-14 Dexcel Pharma Technologies, Ltd. Specific time-delayed burst profile delivery system
HU227490B1 (en) * 2005-08-26 2011-07-28 Egis Gyogyszergyar Nyilvanosan Muekoedoe Reszvenytarsasag Sustained release pharmaceutical preparation containing carvedilol
ES2531215T3 (es) 2006-01-27 2015-03-11 Aptalis Pharmatech Inc Sistemas de administración de fármacos que comprenden un agente de bloqueo selectivo de la serotonina 5-HT3 débilmente básico y ácidos orgánicos
EP1976492B8 (en) * 2006-01-27 2018-07-04 Adare Pharmaceuticals, Inc. Drug delivery systems comprising weakly basic drugs and organic acids
CA2661683C (en) * 2006-08-31 2015-11-24 Eurand, Inc Drug delivery systems comprising solid solutions of weakly basic drugs

Also Published As

Publication number Publication date
PT2265261T (pt) 2016-09-14
KR101660927B1 (ko) 2016-09-28
AR071562A1 (es) 2010-06-30
CL2009000598A1 (es) 2009-08-21
AU2009223019C1 (en) 2015-05-07
US20090232885A1 (en) 2009-09-17
ZA201006557B (en) 2011-12-28
IL208089A0 (en) 2010-12-30
ES2590479T3 (es) 2016-11-22
US8133506B2 (en) 2012-03-13
AU2009223019B2 (en) 2013-10-03
AU2009223019A1 (en) 2009-09-17
CA2718257C (en) 2016-07-19
BRPI0908942A2 (pt) 2017-09-19
SA109300166B1 (ar) 2013-07-04
TW200942273A (en) 2009-10-16
TWI440480B (zh) 2014-06-11
EP2265261A4 (en) 2013-07-03
SG10201405929UA (en) 2014-11-27
JP5634882B2 (ja) 2014-12-03
MX2010010052A (es) 2011-01-25
HUE029680T2 (en) 2017-02-28
CN101977593B (zh) 2014-08-06
EP2265261B1 (en) 2016-07-06
WO2009114606A1 (en) 2009-09-17
DK2265261T3 (en) 2016-10-03
CN101977593A (zh) 2011-02-16
NZ587897A (en) 2012-10-26
RU2504362C2 (ru) 2014-01-20
JP2011513498A (ja) 2011-04-28
RU2010141726A (ru) 2012-04-20
EP2265261A1 (en) 2010-12-29
CA2718257A1 (en) 2009-09-17
KR20100129756A (ko) 2010-12-09

Similar Documents

Publication Publication Date Title
ZA201006557B (en) Drug delivery systems comprising weakly basic drugs and organic acids
ZA200806496B (en) Drug delivery systems comprising weakly basic drugs and organic acids
EP2056792A4 (en) DRUG DELIVERY SYSTEMS WITH SOLID SOLUTIONS FROM LIGHT BASIC ACTIVE SUBSTANCES
HK1214984A1 (zh) 給藥管理系統和方法
IL213376A0 (en) Zaleplon gastroretentive drug delivery system and uses thereof
ZA201101737B (en) Progestin-containing drug delivery system
ZA201002014B (en) Drug delivery system
EP2132133A4 (en) ADMINISTRATION OF PARTICULATE MEDICINE
EP2313122A4 (en) MEDICAL DRUG DELIVERY DEVICE
EP2299989A4 (en) STABILIZED TRANSDERMAL DRUG DISPENSING SYSTEM
EP2178598A4 (en) IONTOPHORETIC DRUG DISTRIBUTION SYSTEM
PL2398500T3 (pl) System dostarczania leków na bazie glutationu
IL210883A0 (en) Drug delivery system and method of munufacturing thereof
BRPI0818129A2 (pt) Sistema de transporte e administração de medicamento seguro
HK1202083A1 (en) Iontophoretic drug delivery system
EP2023900A4 (en) DRUG DELIVERY SYSTEM WITH CONTROLLED DOSES
IL212357A0 (en) Sustained drug delivery system
PL2437736T3 (pl) Systemy dostarczania leków
IL213577A0 (en) Drug delivery device
GB0710522D0 (en) Drug delivery system comprising matrix metalloproteinase inhibitors
EP2398475A4 (en) PHARMACEUTICAL PREPARATION AND DISPOSAL SYSTEM
EP2226083A4 (en) ACTIVE RELEASE SYSTEM
ZA201006517B (en) Estradiol-containing drug delivery system
ZA200901366B (en) Drug delivery systems comprising solid solutions of weakly basic drugs
EP2327388A4 (en) DRUG ADMINISTRATIVE DEVICE AND MEDICINE ADMINISTRATIVE PROCEDURE